Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 4Breast Neoplasms 2Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Plasma Cell 1Neoplasms 1Melanoma 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Brain Neoplasms 1Bone Neoplasms 1

Interventions

Radiosurgery 23Temozolomide 9Radiotherapy 8pembrolizumab 6Cyclophosphamide 6abemaciclib 5Nivolumab 5Radiation 4Mental Status and Dementia Tests 4Bevacizumab 4trastuzumab deruxtecan 3trametinib 3pertuzumab 3osimertinib 3entrectinib 3Surveys and Questionnaires 3Proton Therapy 3Magnetic Resonance Spectroscopy 3Lomustine 3Ipilimumab 3Immunoglobulin G 3Disulfides 3Cisplatin 3tucatinib 2encorafenib 2binimetinib 2Vincristine 2Trastuzumab 2Surgical Procedures, Operative 2Spermine Synthase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Brain Neoplasms × poly ICLC × Clear all
NCT03223103 2025-09-10

Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma

Albert Einstein College of Medicine

Phase 1 Active not recruiting
13 enrolled
CNS

Brain Neoplasms, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡